Frank Vinluan
Xconomy
North Carolina, United States
Contact Frank
Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.
| Recent: |
|
| Past: |
|
Past articles by Frank:
Xconomy: Vertex Stops Test of Rare Disease Drug, Dimming Pipeline Prospects
Vertex Pharmaceuticals is halting work on an experimental drug for a rare protein deficiency after safety problems were reported in Phase 2 testing. The → Read More
Xconomy: Codiak Bio’s IPO Brings In $82M as Exosome Clinical Trials Begin
Codiak BioSciences now has $82.5 million to fund clinical tests of a new class of medicines based on exosomes, tiny bubbles formed by cells that the → Read More
Xconomy: Roche Enlists Dyno to Bring AI to Next-Generation Liver, CNS Gene Therapies
Roche made a splash with its acquisition of Spark Therapeutics, whose Luxturna, a gene therapy for an inherited form of vision loss, was the first such → Read More
Xconomy: Despite Phase 2 Failure, Gossamer Bio Sees a Path for Drug in Asthma
Gossamer Bio’s lead drug, an experimental treatment for asthma and allergies, has failed in two mid-stage clinical trials but the biotech sees enough in → Read More
Xconomy: “Opioid Stacking” Concerns Lead FDA to Reject Avenue Therapeutics Drug
An opioid that Avenue Therapeutics reformulated for treating post-surgical pain in hospital settings has been rejected by the FDA due to safety concerns. → Read More
Xconomy: FDA Panel Vote Weighs in Favor of Alkermes Psych Drug, With Caveats
An Alkermes antipsychotic treatment designed to offer the benefits of a commonly prescribed medicine, but without the weight gain side effect, won the → Read More
Xconomy: In RNAi Move, Takeda Fronts $300M to Team Up on Arrowhead Liver Drug
Arrowhead Pharmaceutical’s gene silencing treatment for a rare liver disease will move through the regulatory process and potential commercialization with → Read More
Xconomy: Scribe Therapeutics Sets Out to Write CRISPR Gene Editing’s Next Chapter
The first generation of CRISPR-based therapies showed how the technology can edit DNA, making genetic fixes to unwanted mutations. But those treatments → Read More
Xconomy: Federation Bio Bags $50M to Engineer New Approach to Microbiome Drugs
Scientists at microbiome therapy developers often talk about the importance of community, how the bugs in our gut act in concert in addition to → Read More
Xconomy: Bristol Myers to Buy MyoKardia, FDA-Ready Heart Disease Drug for $13.1B
Bristol Myers Squibb is bolstering its cardiovascular drug lineup with a $13.1 billion deal to acquire MyoKardia, a company whose experimental therapy for → Read More
Xconomy: FDA Lifts Solid Bio Clinical Hold, Duchenne Study Cleared to Resume
Solid Biosciences has answered the FDA’s outstanding questions about its Duchenne muscular gene therapy, clearing a clinical trial to now resume after → Read More
Xconomy: Genfit Restructuring Cuts Staff by 40%, Creates Two New Subsidiaries
Genfit is halting all work on its lead drug in the fatty liver disorder nonalcoholic steatohepatitis (NASH) and implementing a corporate restructuring → Read More
Xconomy: Pfizer Pumps $200M Into CStone for Rights to PD-L1 Cancer Drug in China
CStone Pharmaceuticals has touted its experimental drug sugemalimab as potentially the best in its class of cancer immunotherapies. Pfizer is placing a → Read More
Xconomy: Orphazyme Stock Sale Reaps $83M as Neimann-Pick Drug Review Begins
Orphazyme has fresh cash from the sale of shares in the US and Europe, which will support its lead rare disease drug through regulatory review and, if → Read More
Xconomy: Praxis Precision Medicines Leads Way as Three More Biotechs Prep IPOs
Praxis Precision Medicines kept mostly quiet about its research on central nervous system disorder (CNS) drugs until May, when it emerged from stealth and → Read More
Xconomy: Galecto Picks Up $64M as Plans for Fibrosis Clinical Trials Move Forward
Had things turned out differently, scientists at Galecto might be watching their idiopathic pulmonary fibrosis drug candidate develop in the hands of a → Read More
Xconomy: Bio Roundup: Grail Acquisition, Libra’s Launch, Tau Trial Results & More
In biotech, you can go home again. Four years ago, Illumina spun out cancer diagnostics startup Grail. This week, the gene sequencing giant announced it → Read More
Xconomy: Monte Rosa Raises $96M for “Glue-Based” Protein Degrading Drugs
Many drugs work by binding to a protein and blocking it. Technology for eliminating disease-causing proteins altogether remains experimental, but this → Read More
Xconomy: Libra Strikes a Balance With Approach to ALS and Other Neuro Disorders
Amyotrophic lateral sclerosis (ALS) has no cure and few available treatments but the past decade has revealed new knowledge about the pathology of the → Read More
Xconomy: Tau-Targeting Alzheimer’s Drug from AC Immune, Roche Fails in Phase 2
An Alzheimer’s disease drug from partners AC Immune and Roche has failed a mid-stage clinical trial, adding another compound to the list of experimental → Read More